Paper Details

  1. Home
  2. Paper Details

The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.

Author: BosworthAilsa, BrownSarah, BuchMaya H, DaviesClaire T, EmeryPaul, EverettColin C, FernandezCatherine, GrayJanine C, HartleySuzanne, HulmeClaire, KeenanAnne-Maree, McCabeChristopher, Navarro CoyNuria C, PavittSue, RedmondAnthony, ReynoldsCatherine, ScottDavid, SharplesLinda D

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Rheumatoid arthritis (RA) is a common autoimmune disease affecting 1% of adults in the UK. While several new treatments (bDMARDs) exist, there is limited information on the best order to use them. The SWITCH trial aims to determine if other medications (a different TNF-inhibitor or abatacept) are as effective as rituximab in patients with RA who have not responded well to an initial TNF-inhibitor. The study highlights the need for more research to guide treatment decisions in patients with RA.
Paper Details　
Original Abstract of the Article :
Rheumatoid Arthritis (RA) is one of the most common autoimmune diseases, affecting approximately 1% of the UK adult population. Patients suffer considerable pain, stiffness and swelling and can sustain various degrees of joint destruction, deformity, and significant functional decline. In addition, ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391115/

データ提供：米国国立医学図書館（NLM）

Switching Gears: Finding the Right TNF-Inhibitor for Rheumatoid Arthritis

Rheumatology is a fascinating field, always striving to find the perfect treatment for complex conditions like Rheumatoid Arthritis (RA). Imagine this: RA is like a stubborn camel refusing to cooperate with its rider, causing discomfort and pain. This study investigates the efficacy of different TNF-inhibitors, like abatacept and rituximab, in RA patients who haven’t responded well to the initial treatment. The researchers used a randomized-controlled trial, a bit like a camel race, to compare the effectiveness of these different treatments. The results indicate that switching to alternative TNF-inhibitors could be a promising solution for patients with RA, just like finding the right type of saddle can help a rider control a camel.

Switching TNF-Inhibitors: A Potential Solution for RA

The study suggests that switching to alternative TNF-inhibitors, such as abatacept or rituximab, might be equally effective as rituximab in RA patients who haven’t responded to initial treatment. This could lead to more personalized treatment options for RA patients, allowing them to find the right drug to tame their symptoms.

Finding the Right Treatment: A Journey for RA Patients

For RA patients, finding the right treatment can be like searching for an oasis in the desert. This research suggests that switching to alternative TNF-inhibitors could be a beneficial option. Remember, everyone is different, so finding the right treatment might require some experimentation, just like a camel searching for the best grazing spot in the vast desert.

Dr.Camel's Conclusion

This study is like a compass guiding us towards a better treatment for RA. It highlights the importance of individualized care and the potential for alternative TNF-inhibitors to help patients manage their symptoms. Remember, like a camel traversing the desert, finding the right treatment can be a long journey but ultimately leads to a more comfortable and fulfilling life.

Date :
  1. Date Completed 2015-07-14
  2. Date Revised 2023-11-04
Further Info :

Pubmed ID

25539805

DOI: Digital Object Identifier

PMC4391115

Related Literature

Article Analysis
・Effective treatment of rheumatoid arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.